Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryNewsCalendarCompanyFinancialsConsensus 
Company
Cyclacel Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious disorders.Its lead candidate, sapacitabine, oral nucleoside analogue prodrug that acts through a novel mechanism.It also develops... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
09/21 Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare..
09/13 CYCLACEL PHARMACEUTICALS INC : Today's Research Reports on Trending Tickers: Cyc..
09/11 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
09/11 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
09/08 Cyclacel Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Globa..
08/10 CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
08/09 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Results of Operations ..
08/09 CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
08/09 CYCLACEL PHARMACEUTICALS : Reports Second Quarter 2017 Financial Results
08/09 Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial Results 
More news
Sector news : Bio Therapeutic Drugs
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Midday Gainers / Losers
2016 Cyclacel's lead product candidates show encouraging results in early-stage st..
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2016 Some Ideas For The Next Celator
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 7,00 $
Spread / Average Target 265%
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICALS INC22
AMGEN28.70%135 544
CELGENE CORPORATION24.61%112 572
GILEAD SCIENCES15.40%108 744
REGENERON PHARMACEUTICALS19.36%46 367
VERTEX PHARMACEUTICALS107.30%38 136